ArticleBMC cancer2017
YRNA expression predicts survival in bladder cancer patients.
Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- hY3 RNA binds and inhibits ribosomes and modulates the starvation-induced integrated stress response.Nucleic acids research · 2026Article
- Expression Levels of Plasma YRNAs in Colorectal Cancer as a Potential Noninvasive Biomarker.Journal of gastrointestinal cancer · 2025Article
- Footprints in the Sno: investigating the cellular and molecular mechanisms of SNORD116.Open biology · 2025Review
- YRNAs: biosynthesis, structure, functions and involvment in cancer development.Discover oncology · 2025Review
- Review
- Exploring the Role of Long Non-Coding RNAs in Predicting Outcomes for Hepatitis B Patients.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Hypoxia-related Y RNA fragments as a novel potential biomarker for distinguishing metastatic oral melanoma from non-metastatic oral melanoma in dogs.The veterinary quarterly · 2024Article
- Characterization of all small RNAs in and comparisons across cultured megakaryocytes and platelets of healthy individuals and COVID-19 patients.Journal of thrombosis and haemostasis : JTH · 2023Article
- Novel Y RNA-Derived Fragments Can Differentiate Canine Hepatocellular Carcinoma from Hepatocellular Adenoma.Animals : an open access journal from MDPI · 2023Article
- The Impact of YRNAs on HNSCC and HPV Infection.Biomedicines · 2023Article
- Characterization of novel small non-coding RNAs and their modifications in bladder cancer using an updated small RNA-seq workflow.Frontiers in molecular biosciences · 2022Article
- Survivin and Her2 Expressions in Different Grades of Urothelial Neoplasms of Urinary Bladder.Iranian journal of pathology · 2021Article
- YRNAs and YRNA-Derived Fragments as New Players in Cancer Research and Their Potential Role in Diagnostics.International journal of molecular sciences · 2020Review
- YRNAs: New Insights and Potential Novel Approach in Head and Neck Squamous Cell Carcinoma.Cells · 2020Article
- Y RNA: An Overview of Their Role as Potential Biomarkers and Molecular Targets in Human Cancers.Cancers · 2020Review
- Article
- Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet.Frontiers in genetics · 2019Review
- Profiling of tRNA Halves and YRNA Fragments in Serum and Tissue From Oral Squamous Cell Carcinoma Patients Identify Key Role of 5' tRNA-Val-CAC-2-1 Half.Frontiers in oncology · 2019Article
- YRNA expression in prostate cancer patients: diagnostic and prognostic implications.World journal of urology · 2018Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-coding RNAs play an important role in human carcinogenesis. YRNAs (Ro-associated Y), a novel class of non-coding RNAs, have been identified as biomarker in various malignancies, but remain to be studied in urinary bladder cancer (BCA) patients.
methodsThe expression of all four YRNAs (RNY1, RNY3, RNY4, RNY5) was determined in archival BCA (urothelial carcinoma, n = 88) and normal urothelial bladder (n = 30) tissues using quantitative real-time PCR. Associations with clinicopathological parameters and prognostic role for overall and cancer-specific survival were analysed.
resultsAll YRNAs were significantly downregulated in BCA tissue. A low expression of RNY1, RNY3 and RNY4 was associated with muscle-invasive BCA, lymph node metastases and advanced grade. Furthermore, expression of RNY1 and RNY3 was predictive for BCA patients' overall (also RNY4) and cancer-specific survival as estimated using Kaplan-Meier and univariate (but not multivariate) Cox regression analyses. RNY1, RNY3 and RNY4 show good discriminative ability between tumor and normal tissue, as well as between muscle-invasive and non-muscle-invasive urothelial carcinoma.
conclusionsThe expression of YRNAs is altered in BCA and associated with poor prognosis. Possible diagnostic role of YRNAs should be investigated in further studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.